GIOVANNA FATTOVICH,* GIULIANO GIUSTINA,‡ FRANCOISE DEGOS, § FEDERICO
TREMOLADA,‡ GIULIO DIODATI,‡ PIERO ALMASIO, x FREDERIK NEVENS, Ø ANTONIO …

One hundred and five hepatitis B surface antigen (HBsAg) positive patients presenting with
chronic persistent hepatitis (n= 46) or chronic active hepatitis without cirrhosis (n= 59) were …

BACKGROUND The effect of hepatitis delta virus (HDV) infection on the clinical course of
cirrhosis type B is poorly defined. AIMS To investigate the impact of HDV status on morbidity …

To examine the morbidity of compensated cirrhosis type B, a cohort of 349 Western
European, white patients (86% men; mean age, 44 years) with biopsy-proven cirrhosis was …

Aims: The aim of this study was to assess the incidence of fatal, life-threatening side effects
and the de novo appearance of non-hepatic morbidity during interferon alfa therapy for …

A multicenter longitudinal study was performed to assess the survival of hepatitis B surface
antigen positive compensated cirrhosis, primarily in relation to hepatitis B virus replication …

The aim of this study was to evaluate whether interferon alfa (IFN‐α) treatment‐associated
virological and biochemical remission improves survival in a cohort of 90 white patients with …

Objective: The aim of this study was to evaluate the incidence, prognostic factors and clinical
significance of delayed clearance of serum HBsAg in compensated cirrhosis B. Methods …

Background/Aims: The role of interferon alfa treatment in improving morbidity endpoints in
patients with chronic hepatitis C infection is currently under debate. The aim of this study …

One hundred eighty-four patients with hepatitis B surface antigen-positive chronic hepatitis
were evaluated for antibodies to hepatitis C virus (anti-HCV). Only 11 (8%) of 136 patients …